Phenotype Affects Oxcarbazepine Tx in Peripheral Neuropathic Pain

the MPR take:

Oxcarbazepine is FDA-approved for the treatment of seizure disorder, but its use as a potential therapy for the treatment of peripheral neuropathic pain is explored in a new study published in the journal Pain. In the study patients, were randomized to receive either oxcarbazepine (1800–2400mg) or placebo for two, 6-week treatment periods.  Since treatment response has been shown to be affected by pain phenotype, researchers also wanted to explore whether subjects with different pain phenotypes (irritable nociceptor phenotype vs. non-irritable nociceptor phenotype) responded differently to treatment. In all patients, oxcarbazepine relieved pain 0.7 points more than placebo (using numeric rating scale). Study results also showed that oxcarbazepine treatment was more efficacious in relieving peripheral neuropathic pain in patients with the irritable nociceptor phenotype vs. patients who had the non-irritable nociceptor phenotype.

Abstract: In neuropathic pain it has been suggested that pain phenotype based on putative pain mechanisms may predict response to treatment. This was a randomised, double-blind, placebo-controlled, and phenotype-stratified study with two 6-week treatment periods of oxcarbazepine (1800–2400mg) and placebo.